Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Posted on by

The Lancet
Apr 02, 2022 Volume 399 Number 10332 p1279-1358, e20-e29
https://www.thelancet.com/journals/lancet/issue/current

 

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
Akash Khobragade, et al. on behalf of the ZyCoV-D phase 3 Study Investigator Group